ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0144

The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease

Guy Katz1, Amelia S. Cogan1, Grace McMahon1, Sebastian Perez-Espina1, Ana Fernandes1, Cory Perugino1, Zachary Wallace1, John Atkinson2, Alfred Kim2 and John Stone3, 1Massachusetts General Hospital, Boston, MA, 2Washington University School of Medicine, St. Louis, MO, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2022

Keywords: complement, IgG4 Related Disease, immunology, Renal

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated disease that can affect nearly every organ in the body. Hypocomplementemia is common in some patients with IgG4-RD, suggesting that complement activation may be involved in the disease pathophysiology. Hypocomplementemia may be especially common in patients with renal involvement of IgG4-RD. We aimed to evaluate the association of patient characteristics with hypocomplementemia in our large IgG4-RD cohort.

Methods: Patients identified through the Massachusetts General Hospital IgG4-RD cohort were included in this study if they fulfilled the 2019 ACR/EULAR IgG4-RD Classification Criteria or had “probable” IgG4-RD. Probable IgG4-RD is defined as: 1) typical organ involvement; 2) no exclusion criteria present; 3) insufficient total classification points (< 20). The usual scenarios for a diagnosis of probable IgG4-RD are when biopsy is non-diagnostic or not obtained. Hypocomplementemia was defined as any measurement of serum C3 or C4 complement below the lower limit of normal (LLN). Disease characteristics were extracted via review of medical records. Statistical analyses were unpaired T-tests and Chi-squared tests.

Results: Hypocomplementemia was identified in 91 (30%) of 306 patients in the cohort. Characteristics of patients with and without hypocomplementemia are summarized in Table 1. Patients with hypocomplementemia were less likely to have normal serum IgG4 (11% vs. 26%, p=0.009) and more likely to have highly elevated (above 5x the upper limit of normal) serum IgG4 (52% vs. 28%, p=0.001). Patients with hypocomplementemia had more organs involved (mean 4.3 vs. 2.9, p< 0.001). Among patients with hypocomplementemia, C3 was low in 79%, C4 in 84%, and both in 64%. 17% of C3 troughs and 43% of C4 troughs were at or below one-half of the LLN for the assay.

Patients with vs. without hypocomplementemia more commonly had submandibular gland, lymph node, lung, liver, and renal involvement as well as constitutional symptoms (Figure 1). Retroperitoneal involvement was unusual among hypocomplementemic patients. Of the 84 patients with IgG4-related kidney disease (IgG4-RKD), 38 (45%) had hypocomplementemia. Hypocomplementemic patients with IgG4-RKD had significantly more organs involved (mean 5.2 vs. 3.7, p=0.005), more commonly had both low C3 and C4 complement (84% vs. 47%, p=0.03), and more commonly had C3 or C4 troughs at or below one-half of the LLN (24% vs. 6%, p=0.02 for C3; 66% vs. 26%, p=0.003 for C4) than those without IgG4-RKD (Table 2).

Conclusion: Hypocomplementemia is common, and often profound, in IgG4-RD and is associated with serum IgG4 concentration and multiorgan involvement. Additional investigations are needed to describe the nature of complement activation and its role in disease activity, both in the kidneys and beyond.

Supporting image 1

Table 1. Characteristics of IgG4-RD patients with and without hypocomplementemia. *IgG4 concentration was not available for one patient without hypocomplementemia. Values are reported as n (%) unless noted otherwise. ULN: upper limit of normal, LLN: lower limit of normal; SD: standard deviation.

Supporting image 2

Figure 1. IgG4-RD manifestations in patients with and without hypocomplementemia. *Signifies P<0.05.

Supporting image 3

Table 2. Hypocomplementemic patients with and without IgG4-related kidney disease. Values are reported as n (%) unless noted otherwise. ULN: upper limit of normal, LLN: lower limit of normal; SD: standard deviation.


Disclosures: G. Katz, None; A. Cogan, None; G. McMahon, None; S. Perez-Espina, None; A. Fernandes, None; C. Perugino, None; Z. Wallace, Sanofi, Bristol-Myers Squibb(BMS), Zenas Biopharma, Horizon, Shionogi; J. Atkinson, Compliment Corporation, Kypha, Inc., Gemini Therapeutics, Q32 Bio, Celldex Therapeutics, Clinical Pharmacy Services, CDMI, Kairos Bioconsulting, LLC, Achillion Pharmaceuticals, Inc, BioMarin Pharmaceutical Inc., Annexon Biosciences, Inc., Alexion Pharmaceuticals, Broadwing Bio, LLC; A. Kim, GlaxoSmithKline, Kypha Inc., Foghorn Therapeutics, Aurinia Pharmaceuticals, Exagen Diagnostics, Alexion Pharmaceuticals, Pfizer, AstraZeneca; J. Stone, Horizon Theraputics, Sanofi, Amgen, Argenx, Bristol-Myers Squibb(BMS), Chemocentryx, Kyverna, Novartis, Palleon Pharmaceuticals, PPD, Q32, Star Therapeutics, Roche, Mirabio, Spruce Biosciences, Steritas, Zenas.

To cite this abstract in AMA style:

Katz G, Cogan A, McMahon G, Perez-Espina S, Fernandes A, Perugino C, Wallace Z, Atkinson J, Kim A, Stone J. The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-association-of-hypocomplementemia-with-organ-involvement-and-serum-igg4-in-igg4-related-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-of-hypocomplementemia-with-organ-involvement-and-serum-igg4-in-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology